---
title: "INmune Bio Inc. Switches Auditors Following Marcum LLP's Attest Business Acquisition by CBIZ CPAs"
description: "INmune Bio Inc. has changed its independent registered public accounting firm, dismissing Marcum LLP following its acquisition by CBIZ CPAs P.C. on November 1, 2024. The decision, approved by the audi"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/239206753.md"
published_at: "2025-05-07T21:54:25.000Z"
---

# INmune Bio Inc. Switches Auditors Following Marcum LLP's Attest Business Acquisition by CBIZ CPAs

> INmune Bio Inc. has changed its independent registered public accounting firm, dismissing Marcum LLP following its acquisition by CBIZ CPAs P.C. on November 1, 2024. The decision, approved by the audit committee, comes after Marcum's audit report expressed substantial doubt about INmune Bio's ability to continue as a going concern. CBIZ CPAs will serve as the new auditor for the fiscal year ending December 31, 2025. There were no disagreements affecting the financial statements between INmune Bio and Marcum.

INmune Bio Inc. recently announced a change in its independent registered public accounting firm. On November 1, 2024, CBIZ CPAs P.C. acquired the attest business of Marcum LLP. Consequently, on May 7, 2025, INmune Bio Inc. dismissed Marcum as its independent registered public accounting firm, a decision approved by the company’s audit committee. Marcum’s audit report on INmune Bio’s financial statements for the fiscal years ending December 31, 2024, and 2023 did not contain any adverse opinions but included a note expressing substantial doubt about the company’s ability to continue as a going concern. On the same day, CBIZ CPAs was engaged as the new independent registered public accounting firm for the fiscal year ending December 31, 2025. There were no disagreements or reportable events between INmune Bio and Marcum that impacted the financial statements. Marcum has agreed with the statements made by INmune Bio regarding this transition. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-040727), on May 07, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [INMB.US - Inmune Bio](https://longbridge.com/en/quote/INMB.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| INmune Bio Submits CORDStrom Pre-Submission Package to UK MHRA for RDEB Review | INmune Bio Inc. has submitted a pre-submission package to the UK MHRA for CORDStrom™, a treatment for recessive dystroph | [Link](https://longbridge.com/en/news/275461922.md) |
| INmune Bio Unveils Phase 2 Alzheimer's Trial Results at CTAD Conference | INmune Bio Inc. will present Phase 2 trial results of XPro1595 for early Alzheimer's at the CTAD conference in San Diego | [Link](https://longbridge.com/en/news/266435841.md) |
| INmune Bio Reports Positive Phase 2 Imaging Data for XPro1595 in Early Alzheimer's Disease | INmune Bio Inc. announced positive Phase 2 neuroimaging data for XPro1595 in early Alzheimer's disease patients with hig | [Link](https://longbridge.com/en/news/268090334.md) |
| INmune Bio Inc. Updates Executive Compensation Agreements | INmune Bio Inc. has updated the employment agreements for its President and CEO, David J. Moss, and CFO, Cory Ellsperman | [Link](https://longbridge.com/en/news/268487050.md) |
| INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives \| INMB Stock News | INmune Bio, Inc. (NASDAQ: INMB) has issued a shareholder letter reflecting on 2025 milestones and outlining strategic in | [Link](https://longbridge.com/en/news/273859605.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.